In light of recent findings, would you consider prescribing dutasteride to men with low-risk prostate cancer to reduce their risk of PCa progression?

Share this article:

A randomized, double-blind study published recently in The Lancet showed that men on active surveillance for low-risk prostate cancer (PCa) who received the 5α-reductase inhibitor dutasteride for three years had a significant 38% decreased risk of PCa progression compared with men who took placebo. The investigators concluded that their findings “show that dutasteride could be a beneficial adjunct to active surveillance for men with low-risk prostate cancer, delaying their time to pathological progression and initiation of primary therapy.”

Renal & Urology News would like to ask its urologist readers the following question.


Leave a comment below to explain your choice.
Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

How do you feel about on-call emergency department coverage?

How do you feel about on-call emergency department ...

The nation's community hospitals are facing increasing problems obtaining emergency on-call coverage.

Have you ever recommended acupuncture to a patient?

Have you ever recommended acupuncture to a patient?

Evidence suggests acupuncture may help ease certain types of pain and perhaps other conditions

Are you more likely to perform partial rather than radical nephrectomy for tumors if robotic-assisted surgery is available?

Are you more likely to perform partial rather ...

Availability of robotic-assisted surgery at a hospital was independently associated with greater use of partial nephrectomy.